Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings.

Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings.
复制标题

DOI:
10.3390/cells10102581
复制
发表时间:
2021-09-28
期刊:
影响因子:
6
通讯作者:
Budni J
Budni J
中科院分区:
生物学2区
文献类型:
--
作者:
de Oliveira J;Kucharska E;Garcez ML;Rodrigues MS;Quevedo J;Moreno-Gonzalez I;Budni J

文献摘要

参考文献

被引文献

相似文献

阿尔茨海默病(AD)是世界范围内导致痴呆的主要原因。大多数AD患者在晚年发展为晚发性AD(LOAD)。目前,对AD病理最公认的解释是淀粉样级联假说。淀粉样β蛋白(Aβ)的聚集和沉积被认为是AD的关键致病过程,导致淀粉样斑块的形成,以及神经原纤维缠结、神经细胞死亡、突触变性和痴呆。在LOAD中,Aβ积聚和神经元丢失的原因尚不完全清楚。重要的是,血脑屏障(BBB)的破坏似乎在诱导神经炎症和随后的AD发展中起着至关重要的作用。此外,我们认为由代谢性疾病或感染等条件引发的全身性炎症是血脑屏障破坏、共存的炎症级联以及最终在AD中观察到的神经退行性变的原因。在这方面,使用抗炎分子可能是一种有趣的治疗、延迟甚至阻止AD发病和进展的策略。在此,我们对AD发病机制中的炎性级联反应和潜在机制进行综述,并对化合物的抗炎作用进行综述。
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Most AD patients develop the disease in late life, named late onset AD (LOAD). Currently, the most recognized explanation for AD pathology is the amyloid cascade hypothesis. It is assumed that amyloid beta (Aβ) aggregation and deposition are critical pathogenic processes in AD, leading to the formation of amyloid plaques, as well as neurofibrillary tangles, neuronal cell death, synaptic degeneration, and dementia. In LOAD, the causes of Aβ accumulation and neuronal loss are not completely clear. Importantly, the blood–brain barrier (BBB) disruption seems to present an essential role in the induction of neuroinflammation and consequent AD development. In addition, we propose that the systemic inflammation triggered by conditions like metabolic diseases or infections are causative factors of BBB disruption, coexistent inflammatory cascade and, ultimately, the neurodegeneration observed in AD. In this regard, the use of anti-inflammatory molecules could be an interesting strategy to treat, delay or even halt AD onset and progression. Herein, we review the inflammatory cascade and underlying mechanisms involved in AD pathogenesis and revise the anti-inflammatory effects of compounds as emerging therapeutic drugs against AD.
DOI: 10.3233/jad-200064
发表时间: 2020-01-01
影响因子: 4
作者:
Beydoun, May A.;Beydoun, Hind A.;Zonderman, Alan B.
通讯作者: Zonderman, Alan B.
DOI: 10.1002/alz.12068
发表时间: 2020-03-01
影响因子: 14
作者:
通讯作者: --
DOI: 10.1016/j.jalz.2010.12.014
发表时间: 2011-07
期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子: --
作者:
Breitner JC;Baker LD;Montine TJ;Meinert CL;Lyketsos CG;Ashe KH;Brandt J;Craft S;Evans DE;Green RC;Ismail MS;Martin BK;Mullan MJ;Sabbagh M;Tariot PN;ADAPT Research Group
通讯作者: ADAPT Research Group
DOI: 10.1212/wnl.44.2.227
发表时间: 1994-02-01
期刊: NEUROLOGY
影响因子: 9.9
作者:
BREITNER, JCS;GAU, BA;ANTHONY, JC
通讯作者: ANTHONY, JC
DOI: 10.1371/journal.pone.0225487
发表时间: 2020
期刊: PloS one
影响因子: 3.7
作者:
C RC;Lukose B;Rani P
通讯作者: Rani P